Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shared Medical Systems Corp.

This article was originally published in The Gray Sheet

Executive Summary

Anti-takeover shareholder rights plan is amended to delete all provisions requiring certain actions under the plan to be authorized by "continuing directors," the firm announces March 20. The order was taken to "conform the terms of the plan to recent decisions by the Delaware courts." Rebuffed suitor Eclipsys, which launched an unsolicited $2 bil. merger proposal March 2, had filed suit in Delaware Chancery Court challenging the legality of the "continuing director provision" of SMS' "poison pill" shareholder rights plan (1"The Gray Sheet" March 13, p. 14). SMS has scheduled its annual shareholders meeting for June 9, instead of May 16 as previously anticipated, to allow more time for the firm to evaluate various strategic alternatives

Latest Headlines
See All
UsernamePublicRestriction

Register

MT013167

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel